Exelixis (EXEL) Non-Current Deffered Revenue (2010 - 2023)
Exelixis (EXEL) recorded quarterly Non-Current Deffered Revenue of $6.7 million in Q2 2023, up 6.75% quarter-over-quarter from $6.3 million in Q1 2023, and down 6.73% on a YoY basis from $7.2 million in Q2 2022.
Exelixis (EXEL) Non-Current Deffered Revenue (2010 - 2023) Analysis & Trends
Exelixis' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $6.7 million for Q2 2023.
- In Q2 2023, Non-Current Deffered Revenue fell 6.73% year-over-year to $6.7 million; the TTM figure through Jun 2023 stood at $6.7 million (down 6.73% YoY), while the FY2022 annual figure was $6.6 million, down 24.68% from the prior year.
- Non-Current Deffered Revenue was $6.7 million for Q2 2023 at Exelixis, up from $6.3 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $16.6 million in Q2 2019 to a low of $3.8 million in Q1 2021.
- Historically, Non-Current Deffered Revenue has averaged $9.3 million across 5 years, with a median of $8.4 million in 2019.
- The sharpest annual moves came in 2019 and 2020: Non-Current Deffered Revenue jumped 579.01% in 2019, then sank 58.51% in 2020.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $15.4 million in 2019, then slumped by 39.47% to $9.3 million in 2020, then slipped by 6.25% to $8.7 million in 2021, then fell by 24.68% to $6.6 million in 2022, then rose by 2.16% to $6.7 million in 2023.
- The last three Non-Current Deffered Revenue figures came in at $6.7 million (Q2 2023), $6.3 million (Q1 2023), and $6.6 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Exelixis | 13.72 Bn | 12.95 Bn | 590.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 6.72 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Dec 30, 2022 | 6.58 Mn |
| Sep 30, 2022 | 6.49 Mn |
| Jul 1, 2022 | 7.21 Mn |
| Apr 1, 2022 | 8.04 Mn |
| Dec 31, 2021 | 8.74 Mn |
| Oct 1, 2021 | 9.44 Mn |
| Jul 2, 2021 | 8.58 Mn |
| Apr 2, 2021 | 9.76 Mn |
| Jan 1, 2021 | 3.76 Mn |
| Oct 2, 2020 | 9.32 Mn |
| Jul 3, 2020 | 15.00 Mn |
| Apr 3, 2020 | 14.13 Mn |
| Jan 3, 2020 | 6.60 Mn |
| Sep 27, 2019 | 15.40 Mn |
| Jun 28, 2019 | 16.63 Mn |
| Mar 29, 2019 | 8.32 Mn |
| Dec 28, 2018 | 15.90 Mn |
| Sep 28, 2018 | 2.27 Mn |